H. Lundbeck AS (LTS:0ABR) Dividends Paid

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0ABR H. Lundbeck AS LTS:0ABR
72 GF Score
Price kr40.50
GF Value kr38.34
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is H. Lundbeck AS Dividends Paid?

Dividends Paid only applicable to companies reporting Cash Flow from Operations in direct method.

LTS:0ABR
72GF Score
H. Lundbeck AS LTS:0ABR
Dividends Paid is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is H. Lundbeck AS (LTS:0ABR) Overvalued in 2026?

Based on GuruFocus' analysis, H. Lundbeck AS stock appears to be overvalued. The current stock price of kr40.50 is trading 5.6% above its estimated GF Value™ of kr38.34. GuruFocus considers H. Lundbeck AS to be Fairly Valued.

Key valuation signals for LTS:0ABR:

  • Dividends Paid:
  • GF Value™: kr38.34 vs. price of kr40.50 (5.6% above fair value)
  • GF Score™: 72/100 with 5 warning signs

No single metric tells the full story. See the LTS:0ABR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

H. Lundbeck AS Business Description

Address Ottiliavej 9, Valby, DNK, 2500
H. Lundbeck A/S is a Danish pharmaceutical company focused on brain health, specializing in the research, development, and commercialization of treatments for central nervous system disorders. Its portfolio spans antidepressants, antipsychotics, and antiepileptics, with key products including Abilify Maintena and Rexulti for schizophrenia and adjunctive depression, Brintellix/Trintellix for major depressive disorder, Northera for neurogenic orthostatic hypotension, Onfi and Sabril for epilepsy, and Vyepti for migraine prevention. Lundbeck also markets alcohol dependence and Alzheimer's-related therapies. The company sells primarily to hospitals, psychiatrists, neurologists, and other specialists through its own sales forces and partnerships, with North America generating the largest share of revenue, followed by Europe and international markets including Asia. Revenue comes mainly from product sales, supplemented by licensing and collaboration income, and Lundbeck invests heavily in late-stage clinical research and pipeline expansion.
72GF Score

Get the complete analysis for LTS:0ABR

Dividends Paid is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr40.50
Price
kr38.34
GF Value